Background: It is currently unclear if carotid artery stenting (CAS) is as safe as carotid endarterectomy (CEA) for patients with significant asymptomatic stenosis. The aim of our study was to perform a systematic review and meta-analysis of trials comparing CAS with CEA.
At present, there is no trial evidence available to support the hypothesis that carotid artery stenting (CAS) for asymptomatic carotid stenosis is either superior or inferior to carotid endarterectomy (CEA). The observations that CAS for symptomatic patients is indeed inferior in the short term to CEA, as demonstrated by previous randomized controlled trials (RCTs), 1, 2 have not been replicated so far for asymptomatic stenosis because the original trials might have been underpowered or had a noninferiority design. [3] [4] [5] This might have also been a result of the fact that asymptomatic patients have a very low risk of events likely to be similar in the CAS and CEA group owing to the mostly stable nature of the carotid atheroma, which is less likely to produce distal embolization as a result of wire and catheter manipulations in CAS compared with symptomatic patients. Therefore, a clinical equipoise of CAS and CEA in asymptomatic patients may well be hypothesized. The aim of this investigation was to perform a systematic review of the literature and meta-analysis of RCTs comparing CAS with CEA, restricted to asymptomatic carotid stenosis; this was an update of a similar metaanalysis performed by the second author 5 years ago, 6 thought to be necessary in view of the recently published RCTs in asymptomatic patients. 5, 7 From the Department of Vascular Surgery, University of Patras Medical School, Patras a
METHODS
On May 30, 2016, we conducted a literature search on MEDLINE, Cochrane Central Register of Controlled Trials, and Scopus electronic databases using the keywords "carotid endarterectomy and carotid stenting," with no date limit, to identify RCTs comparing CEA with CAS, followed by a manual search of the reference list of the full-text articles and similar meta-analyses to identify additional trials. Our search was fully updated on March 17, 2017 . We opted to include only RCTs in our metaanalysis, which is the best way to adjust potential bias introduced by case-controlled trials in which cases not favorable for CAS or CEA are allocated to the alternative group, respectively. Studies published in languages other than English were not considered, but unpublished data (eg, from the authors of the included studies) were requested. RCTs were identified by two of the authors (S.K.K. and I.K.), and any disagreement was resolved by discussion. The study selection process (Preferred Reporting Items for Systematic Reviews and MetaAnalyses flow diagram) is shown in Fig 1. For each RCT included in the study, raw data (number of patients who developed an end point and total number of patients in the intervention and control groups) were independently extracted by two of the authors (S.K.K. and I.K.) and entered into data sheets. All entries were compared; any disagreement was resolved by discussion, and once confirmed, they were entered into the metaanalysis software.
Outcome measures. Stroke or death rate at 30 days was the primary safety outcome, and ipsilateral stroke at 1 year (including ipsilateral stroke and death rate at 30 days) was the primary efficacy outcome of our study. In case long-term results were not available, the corresponding short-term results were provided. To minimize excessive imbalance in follow-up, because of the variable length of observations for the included studies, only midterm results (ie, up to 5 years) were considered. Secondary outcomes included perioperative stroke, ipsilateral stroke, myocardial infarction (MI), and cranial nerve injury (CNI). We planned subgroup analyses for studies performed in standard and high surgical risk patients.
Methodologic assessment. The methodologic quality of the RCTs was assessed with the risk of bias assessment tool of the Review Manager software (RevMan version 5.3.5; The Nordic Cochrane Centre, Copenhagen, Denmark). An independent assessment was performed by two of the authors (S.K.K. and I.K.); any disagreement was resolved by discussion. whereas larger values are consistent with increasing heterogeneity. An I 2 >50% is indicative of substantial heterogeneity. Sensitivity analysis was planned in case heterogeneity was present, but this was not required. The quality of evidence was graded high, moderate, low, and very low on the basis of risk of bias, directness of evidence, heterogeneity, precision of effects estimates, and risk of publication bias; this was performed using the method developed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group. A "summary of findings" table was created using GRADEprofiler (version 3.6.1), which included the two primary and all secondary outcome measures. The assumed control intervention risks were calculated from the mean number of events in the control groups of the included studies for each outcome.
RESULTS
We identified 3871 records (after removing the duplicates) on literature search (Fig 1) . Some 3824 of them were excluded on the basis of their title and abstract, and an additional 12 records were excluded because they were RCTs in symptomatic patients (n ¼ 4), had a nonrandomized (n ¼ 2) or retrospective (n ¼ 1) design, were published in a non-English language (n ¼ 2), had an irrelevant study protocol (n ¼ 1), or were a comment to a study (n ¼ 1) and because full text could not be acquired in a study with mixed symptomatic and asymptomatic patients (n ¼ 1), which left 35 records in the search. An additional record identified through hand searching was added so that the total number of relevant records was 36, which reported on nine RCTs included in the study.
3-5,7-38 A summary of these nine RCTs is provided in Table I . Five additional RCTs were identified for this update of the meta-analysis. 6 These nine RCTs included a total of 3709 patients allocated to CEA (n ¼ 1479) or CAS (n ¼ 2230). One study was excluded from quantitative meta-analysis because only death rates at 3 months were provided, 29 which left eight RCTs for quantitative analysis. Additional information for the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) was obtained from a metaanalyses the authors have published. 39 Risk of bias and summary graphs are shown in Figs 2 and 3. These demonstrated a low risk of bias in most attributes; as expected, risk for performance bias (blinding of participants and personnel) was high for all these interventional trials. Detection bias (blinding of outcome Quality of the evidence according to the GRADE system. A detailed assessment of all study outcomes appears in Table II . The early outcome of stroke or death rate at 30 days and also the late outcome of stroke or death rate at 30 days plus ipsilateral stroke during followup were both downgraded because of risk of bias and imprecision and upgraded because effects were immediately apparent and consistent with RCTs on symptomatic patients. There was moderate-quality evidence for these main outcome measures of our meta-analysis. The outcome of MI was downgraded because of risk of bias and impression, leading to low-quality evidence.
High-quality evidence was present for CNI, which was downgraded because of risk of bias and imprecision and upgraded by 2 points because of the large magnitude of the effect.
DISCUSSION
Our meta-analysis has demonstrated that among patients undergoing carotid intervention for asymptomatic stenosis, there is evidence to suggest that CEA had lower 30-day stroke and also stroke or death rates compared with CAS. This safety issue dominated the relative efficacy of the two procedure types during follow-up. Because the quality of the research is moderate, there is a need for further high-quality research before a firm recommendation is made that CAS is indeed inferior or not to CEA. Our meta-analysis has demonstrated that the OR of 30-day stroke and also stroke or death with CAS is about 1.6 compared with CEA; the magnitude of this effect size clearly indicates the presence of a clinically significant difference. Indeed, stroke or death rate at 30 days was significantly higher for CAS (2.94%) than for CEA (1.89%), and this 1% difference may be viewed as being excessively high for the baseline risk of CEA. Nonetheless, this should be taken into account when CAS is suggested for a patient who is at "high risk" for CEA. Contemporary medical treatment, preoperative imaging and selection of patients, surgical and anesthesia techniques, and postoperative care have all significantly improved patient outcomes, as recently outlined by a metaregression analysis. 39 The low evidence of heterogeneity beyond chance in our meta-analysis indicates that the direction of the effect size is similar across studies that span two decades. Of note, a similar increase in risk (relative risk of about 1.5) with CAS has been reported by meta-analyses of symptomatic patients. 6, [40] [41] [42] The fact that the magnitude of the risk estimate is about the same in RCTs of asymptomatic and symptomatic patients indicates that the increased risk with CAS is a result of the increased risk in the control group of CEA, which is higher in symptomatic patients. Nevertheless, the complexity of the mechanisms responsible for perioperative stroke after CEA or CAS, 43, 44 including the operator's experience and temporal proximity with the ischemic event in symptomatic patients, 45, 46 is responsible for the wide variation of stroke and death in contemporary data sets. 45 The loss of significance for ipsilateral stroke alone at 30 days in the comparison of CEA vs CAS can be explained by the reduced number of events compared with the all strokes variable that includes contralateral strokes as well, which are more common in CAS because of brain embolism as a result of aortic arch manipulation. We have not performed subgroup analyses for stroke severity (major vs minor) because the criteria for minor strokes do not indicate full recovery, and therefore there still may be significant residual disability. 5 The outcomes of MI and CNI were less common at 30 days after CAS than after CEA. However, the difference in MI rates between the two groups was not significant, perhaps as a result of type II error; further limitations include the ambiguity and diversity of criteria for MI diagnosis used in the trials. We have opted not to present composite outcomes, as disability after an MI is clearly not equivalent with what is experienced after a postprocedural stroke. In our meta-analysis, CNI at 30 days was significantly lower for CAS compared with CEA (0.11% vs 3.21%, respectively), which has been also observed in a meta-analysis of mainly symptomatic patients. 47 Nevertheless, CNI after CEA has been reported to be temporary in the majority of cases, 32,48 which should not defer patients from having CEA in view of the increased stroke rate with CAS.
Our meta-analysis has demonstrated that the longterm outcome of stroke or death rate at 30 days plus ipsilateral stroke during follow-up was significantly higher for CAS than for CEA (3.64% vs 2.45%, respectively). A similar finding has been reported in a meta-analysis of trials with predominantly symptomatic patients. 49 Although this increased long-term risk may be attributed to ischemic brain lesions after CAS, which increase future cerebrovascular risk, 50 the results of our meta-analysis indicated that most of the risk is the result of perioperative events in both CAS and CEA. Meta-analyses of CAS compared with CEA are abundant. 6, [39] [40] [41] [42] 47, 49, 51 Most of them included only symptomatic patients. A few of them included asymptomatic patients analyzed separately, but because of the small study size, they were underpowered to detect significant differences.
Our meta-analysis has some limitations; quality assessment using the GRADE method of the present meta-analysis that included only RCTs revealed low and moderate evidence for the outcomes of MI and stroke, respectively. This downgrade of the quality of evidence was the result of serious imprecision due to the small number of events detected, indicating that further research may be required with continuing enrollment into ongoing RCTs on asymptomatic carotid stenosis (eg, Asymptomatic Carotid Surgery Trial [ACST] 2). Also, the number of MIs was too low to permit statistical significance, and more trials are thus required. Nevertheless, the result of our meta-analysis implies that CEA should be considered in preference to CAS, after discussing its indications, benefits, and disadvantages with the patients and referring physicians, taking into account the already known negative effect of age on CAS outcome. 52 Future work could formally explore the effects of the patient's age and publication year on the effect size of the outcome measures; however, the lack of heterogeneity in all forest plots indicates the lack of any changes in the relative safety and effectiveness of CAS over CEA during the period in which these studies were conducted. In addition, the relatively small number of trials included in the present meta-analysis did not allow us to proceed with an adequate, formal estimation of publication bias.
CONCLUSIONS
Among patients with asymptomatic carotid stenosis who are candidates for carotid intervention, there is evidence to suggest that CAS had higher 30-day stroke or death rates compared with CEA. The long-term efficacy of CEA in ipsilateral stroke prevention, taking into account perioperative stroke and death, was preserved during follow-up. Because the research is judged to be of moderate quality, due to serious risk of bias and imprecision, there is an urgent need for further high-quality research. We would like to thank David Skoloudík for providing information on asymptomatic patients included in his trial. 
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